| pHIVy patients (# = 21) | npHIVy patients (# = 19)a | HC (# = 40) |
---|---|---|---|
Age (years); median (IQR) | 27 (24–29) | 27 (24–29) | 28 (24–31) |
Males; patients (%) | 7 (33) | 12 (63) | 19 (47.5) |
CD4/μl; median (IQR) | 803 (526–1052) | 818 (688–1024) | 851 (643–1099) |
CD4, %; median (IQR) | 33.8 (28.7–38.8) | 38.1 (31.9–42) | 42.9 (39.7–49.4) |
CD8/μl; median (IQR) | 850 (713–1131) | 728 (631–812) | 415 (344–571) |
CD8, %; median (IQR) | 42.8 (32.7–51) | 32.3 (28–40.3) | 22.2 (22.0–22.6) |
CD4/CD8 ratio; median (IQR) | 0.8 (0.6–1.2) | 1.2 (0.8–1.4) | 2.0 (2.0–2.5) |
Years with HIV; median (IQR) | 27* (0) | 4* (3–5.5) | NA |
HIV viral load < 37 copies/ml; patients | 20 | 19 | NA |
Hepatitis B surface antigen positive; patients (%) | 1 (4.76) | 1 (5.26) | NA |
Hepatitis C virus-antibody positive; patients (%)b | 5 (23.81) | 1 (5.26) | NA |
Cytomegalovirus IgG positive; patients (%) | 13 (61.90) | 7 (36.84) | NA |
Toxoplasma gondii IgG positive; patients (%) | 4 (19.04) | 2 (10.52) | NA |
Treatment prescribed at enrolment: | |||
 PI + 2 NRTI; patients (%) | 4 (19) | 5 (26) | NA |
 NNRTI + 2 NRT; patients (%) | 3 (14) | 8 (42) | NA |
 INI + 2 NRTI; patients (%) | 6 (29) | 6 (32) | NA |
 INI + PI; patients (%) | 7 (33) | 0 | NA |
 INI + NNRTI; patients (%) | 1 (5) | 0 | NA |